These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

450 related items for PubMed ID: 10680050

  • 1. Fibrates, dyslipoproteinaemia and cardiovascular disease.
    Watts GF, Dimmitt SB.
    Curr Opin Lipidol; 1999 Dec; 10(6):561-74. PubMed ID: 10680050
    [Abstract] [Full Text] [Related]

  • 2. Mode of action of fibrates in the regulation of triglyceride and HDL-cholesterol metabolism.
    Fruchart JC, Duriez P.
    Drugs Today (Barc); 2006 Jan; 42(1):39-64. PubMed ID: 16511610
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Treatment of dyslipidaemias in patients with established vascular disease: a revival of the fibrates.
    Milionis HJ, Elisaf MS, Mikhailidis DP.
    Curr Med Res Opin; 2000 Jan; 16(1):21-32. PubMed ID: 16422031
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Therapeutic effects of fibrates in postprandial lipemia.
    Kolovou GD, Kostakou PM, Anagnostopoulou KK, Cokkinos DV.
    Am J Cardiovasc Drugs; 2008 Jan; 8(4):243-55. PubMed ID: 18690758
    [Abstract] [Full Text] [Related]

  • 10. Comparison of the efficacy of simvastatin and standard fibrate therapy in the treatment of primary hypercholesterolemia and combined hyperlipidemia.
    Bruckert E, De Gennes JL, Malbecq W, Baigts F.
    Clin Cardiol; 1995 Nov; 18(11):621-9. PubMed ID: 8590530
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Balanced pan-PPAR activator bezafibrate in combination with statin: comprehensive lipids control and diabetes prevention?
    Tenenbaum A, Fisman EZ.
    Cardiovasc Diabetol; 2012 Nov 14; 11():140. PubMed ID: 23150952
    [Abstract] [Full Text] [Related]

  • 14. Optimal management of combined dyslipidemia: what have we behind statins monotherapy?
    Tenenbaum A, Fisman EZ, Motro M, Adler Y.
    Adv Cardiol; 2008 Nov 14; 45():127-153. PubMed ID: 18230960
    [Abstract] [Full Text] [Related]

  • 15. Fibrates in 2003: therapeutic action in atherogenic dyslipidaemia and future perspectives.
    Chapman MJ.
    Atherosclerosis; 2003 Nov 14; 171(1):1-13. PubMed ID: 14642400
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. [Diabetic dyslipidaemia and the atherosclerosis].
    Márk L, Dani G.
    Orv Hetil; 2016 May 08; 157(19):746-52. PubMed ID: 27133274
    [Abstract] [Full Text] [Related]

  • 18. Update on the use of fibrates: focus on bezafibrate.
    Goldenberg I, Benderly M, Goldbourt U.
    Vasc Health Risk Manag; 2008 May 08; 4(1):131-41. PubMed ID: 18629356
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Bezafibrate. An update of its pharmacology and use in the management of dyslipidaemia.
    Goa KL, Barradell LB, Plosker GL.
    Drugs; 1996 Nov 08; 52(5):725-53. PubMed ID: 9118820
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.